Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Microbot Medical Inc. - Common Stock (NQ:MBOT)

2.478 -0.031 (-1.25%)
Streaming Delayed Price Updated: 11:05 AM EDT, Jul 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Microbot Medical Inc. - Common Stock

< Previous 1 2 3 4 Next >
Microbot Medical® to Open Inaugural Endovascular Robotics Session at the Society of Robotic Surgery Annual Meeting
Leading Endovascular Innovators to Highlight Emergence and Growth of Robotics in the Specialty 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical® Added to the Russell Microcap® Index
Automatic inclusion in the appropriate growth and value style indexes 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Strengthens Global IP Portfolio with Newly Granted Patent in China
Significant Development Supports Long-Term Global Commercial Strategy of the LIBERTY® System 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Continues to Strengthen Commercial Capabilities in Preparation for the anticipated Q3 2025 Launch of its LIBERTY® Endovascular Robotic System
The addition of the head of Sales Operations & Analytics aims to strengthen sales infrastructure and launch execution 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Selected for Preliminary Inclusion to Russell Microcap® Index
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical® Bolsters Commercial Leadership Team with the Addition of Experienced Healthcare Officers
From Microbot Medical Inc.
Via GlobeNewswire
Global Robotic Exoskeleton Market Size Expected to Reach $30 Billion By 2032 as A.I. Influence Disrupts the Industry
EQNX::TICKER_START (NYSE:KULR),(NASDAQ:CHRW),(NYSE:PBI),(NYSE:GXO),(NASDAQ:MBOT) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Microbot Medical® Shares Results from Its Pivotal Clinical Trial, Achieving 100% Robotic Navigation Success for the LIBERTY® Endovascular Robotic System
From Microbot Medical Inc.
Via GlobeNewswire
Global Robotic Exoskeleton Market Size Expected to Reach $30 Billion By 2032 as A.I. Influence Disrupts the Industry
From FN Media Group LLC
Via GlobeNewswire
REMINDER: Microbot Medical Announces Data from the Company’s ACCESS-PVI trial will be Presented via Podium Presentation at Society of Interventional Radiology Annual Meeting
Company Reaffirms Expected Timing of FDA Decision With Respect to 510(K) Clearance of LIBERTY® During the Current Second Quarter 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Appoints Seasoned Endovascular Sales Executive to Lead its U.S. Sales Activities for LIBERTY® Endovascular Robotic System
From Microbot Medical Inc.
Via GlobeNewswire
Robotic Telesurgery Data from Collaboration with Corewell Health™ Accepted for Presentation at the Cardiovascular Research Technologies Annual Meeting
Research Collaboration demonstrates the feasibility of using the LIBERTY® Endovascular Robotic System between separate and remote facilities in a coronary simulation model 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Closes $13 Million Registered Direct Offering
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Announces $13 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical® Announces Late-Breaking Abstract Acceptance at the Society of Interventional Radiology Annual Meeting
Acceptance reflects the high interest of the SIR scientific committee on the emerging role of endovascular robotics 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical® Strengthens Its Management Team in Support of the Anticipated Commercial Launch of LIBERTY®
Operations Leader to Enhance Operational Efficiencies by Managing Production Scale-up and Cost Reduction Activities to Support Commercialization 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical® Strengthens Its Commercial Capabilities with the Addition of David J. Wilson to the Board of Directors
Mr. Wilson has a Track Record of Leading Product Launches and Achieving Revenue Growth in the Endovascular Devices Market 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Closes $8.6 Million Registered Direct Offering
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Announces $8.6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Raises a Total of Approximately $11.8 Million in Gross Proceeds from Registered Direct Offering and Previously Announced ATM Facility
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Announces $7 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical® Concludes 2024 by Achieving Key Milestones Culminating in FDA Submission for the Commercialization of LIBERTY®
Company Shifts Focus to Preparing for Commercial Launch as it Enters 2025 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical® CEO Harel Gadot to Discuss Endovascular Robotics on Benzinga All Access
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical® Announces FDA Submission for the Commercialization of the LIBERTY® Endovascular Robotic System
From Microbot Medical Inc.
Via GlobeNewswire
Global Medical Service Robotics Market Project to Exceed $20 Billion in 2024 with Additional Growth Expected
EQNX::TICKER_START (NASDAQ:JFBR),(NASDAQ:SERV),(NASDAQ:SYM),(NASDAQ:MBOT),(NYSE:MDT) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Global Medical Service Robotics Market Project to Exceed $20 Billion in 2024 with Additional Growth Expected
From FN Media Group LLC
Via GlobeNewswire
Microbot Medical Announces the Successful Completion of its Pivotal Human Clinical Trial; Accelerates Go-to-Market Strategy to Prepare for Commercial Launch of LIBERTY® during 2Q 2025
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Accelerates Patient Enrollment of its Pivotal Human Clinical Trial; Expects to Complete the Trial Earlier Than Anticipated as 80% of Patients Have Completed Follow up
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System
Completion of enrollment expected in Q4 with FDA submission for commercialization anticipated by the end of 2024 
From Microbot Medical Inc.
Via GlobeNewswire
Microbot Medical Signs Phase 2 Collaboration Agreement with Corewell Health to Advance Remote Telesurgery Using the LIBERTY® Endovascular Robotic System
From Microbot Medical Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.